{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:44:36Z","timestamp":1770749076692,"version":"3.50.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jdcr.2025.04.038","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T02:44:50Z","timestamp":1748400290000},"page":"69-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Ponatinib-induced psoriasis treated with tildrakizumab"],"prefix":"10.1016","volume":"62","author":[{"given":"Kyle","family":"Mueller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drew","family":"Kuraitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdcr.2025.04.038_bib1","article-title":"Ponatinib: an update on its drug targets, therapeutic potential and safety","volume":"1878","author":"Gao","year":"2023","journal-title":"Biochim Biophys Acta (Bba) - Rev Cancer"},{"issue":"7","key":"10.1016\/j.jdcr.2025.04.038_bib2","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s13555-024-01198-w","article-title":"Psoriasis in the era of targeted cancer therapeutics: a systematic review on de novo and pre-existing psoriasis in oncologic patients treated with emerging anti-neoplastic agents","volume":"14","author":"Madan","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"20","key":"10.1016\/j.jdcr.2025.04.038_bib3","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.151911","article-title":"Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris","volume":"6","author":"Shao","year":"2021","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.jdcr.2025.04.038_bib4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaci.2016.07.019","article-title":"An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis","volume":"139","author":"Paller","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.jdcr.2025.04.038_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","article-title":"Novel therapies in plaque psoriasis: a review of tyrosine kinase 2 inhibitors","volume":"13","author":"Martin","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"10.1016\/j.jdcr.2025.04.038_bib6","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1016\/j.jid.2018.05.018","article-title":"Extracellular ATP and IL-23 form a local inflammatory circuit leading to the development of a neutrophil-dependent psoriasiform dermatitis","volume":"138","author":"Diaz-Perez","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"768","key":"10.1016\/j.jdcr.2025.04.038_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abh1083","article-title":"Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis","volume":"16","author":"Neuwirt","year":"2023","journal-title":"Sci Signaling"},{"issue":"1","key":"10.1016\/j.jdcr.2025.04.038_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41467-023-44270-3","article-title":"Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jdcr.2025.04.038_bib9","first-page":"40","article-title":"Tildrakizumab for psoriasis","volume":"42","year":"2019","journal-title":"Aust Prescr"},{"issue":"8","key":"10.1016\/j.jdcr.2025.04.038_bib10","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1111\/jdv.17124","article-title":"Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1","volume":"35","author":"Cantrell","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625002061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625002061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T23:00:51Z","timestamp":1756162851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512625002061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":10,"alternative-id":["S2352512625002061"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.04.038","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ponatinib-induced psoriasis treated with tildrakizumab","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.04.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}